These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27574572)

  • 1. Considerations in the development of generic disease therapies for multiple sclerosis.
    Hua LH; Cohen JA
    Neurol Clin Pract; 2016 Aug; 6(4):369-376. PubMed ID: 27574572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Moss BP; Cohen JA
    Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D
    J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Hartung DM; Johnston KA; Geddes J; Bourdette DN
    Neurology; 2020 Mar; 94(13):e1407-e1414. PubMed ID: 31941796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
    McKeage K
    CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.
    D Alessandro J; Garofalo K; Zhao G; Honan C; Duffner J; Capila I; Fier I; Kaundinya G; Kantor D; Ganguly T
    CNS Neurol Disord Drug Targets; 2017; 16(6):714-723. PubMed ID: 28240190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Review on Copemyl
    Annovazzi P; Bertolotto A; Brescia Morra V; Gasperini C; Montanari E; Navarra P; Patti F; Sormani MP; Ghezzi A
    Neurol Ther; 2017 Dec; 6(2):161-173. PubMed ID: 28762192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
    Towfic F; Funt JM; Fowler KD; Bakshi S; Blaugrund E; Artyomov MN; Hayden MR; Ladkani D; Schwartz R; Zeskind B
    PLoS One; 2014; 9(1):e83757. PubMed ID: 24421904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.
    Pardo G; Boutwell C; Conner J; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2010 Feb; 42(1):40-6. PubMed ID: 20187348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).
    Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R
    J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate for multiple sclerosis.
    La Mantia L; Munari LM; Lovati R
    Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
    Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.